More News

21 Dec 2016 ImmuNext Enters into a Strategic Alliance to Develop Novel Therapies for Autoimmune Diseases
21 Dec 2016 Allergan to Acquire Acelity L.P. Inc.'s LifeCell Corporation for $2.9 Billion
21 Dec 2016 BioInvent announces Cancer Immunotherapy Research Collaboration and License Agreement with Pfizer and issues new shares to Pfizer
21 Dec 2016 Biogen’s Board of Directors Approves Separation of Bioverativ and Declares Special Dividend Distribution of Bioverativ Stock
21 Dec 2016 Novartis bolsters ophthalmology pipeline through acquisition of Encore Vision, Inc.
21 Dec 2016 Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with PsiOxus Therapeutics for NG-348, an “Armed” Oncolytic Virus to Address Solid Tumors
21 Dec 2016 Novartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseases
16 Dec 2016 ElsaLys Biotech acquires rights of Transgene's anti-CD115 antibody
16 Dec 2016 Evotec and Celgene Enter into Drug Discovery Collaboration for Neurodegenerative Diseases
16 Dec 2016 Novartis bolsters innovative dermatology portfolio through acquisition of Ziarco Group Limited
15 Dec 2016 Takara Bio Signs Exclusive License Agreement with Otsuka for the Investigational Cancer Treatment HF10, an Oncolytic Virus
15 Dec 2016 Cancer Research UK and Bicycle Therapeutics Collaborate to Trial New Therapy for Advanced Solid Tumours
15 Dec 2016 Noxxon Pharma signs clinical immuno-oncology collaboration agreement with MSD to study NOX-a12 combined with Keytruda® (pembrolizumab) in pancreatic and colorectal cancer
14 Dec 2016 MacroGenics Highlights Progress at 2016 R&D Day
13 Dec 2016 Pharnext Presents Positive Exploratory Phase 2 Data From PXT864 at the 9th Clinical Trials on Alzheimer’s Disease (CTAD) Conference in San Diego, United States
13 Dec 2016 Ab Initio Announces Strategic Collaboration with Pfizer to Discover GPCR Activating Antibodies
13 Dec 2016 Daiichi Sankyo and DarwinHealth Announce Strategic Partnership to Deploy a Quantitative Systems Biology Discovery Platform to Prioritize Daiichi Sankyo Cancer Enterprise Compounds for Development
12 Dec 2016 Almirall and Nuevolution Enter into a Strategic Collaboration to Develop RORγt Inhibitors for Treatment of Dermatology Diseases & Psoriatic Arthritis
12 Dec 2016 Purdue Pharma and Exicure Announce Strategic Research Collaboration Agreement to Discover and Develop a Treatment for Psoriasis and Other Diseases Utilizing SNA™ Technology
12 Dec 2016 Pioneers in Oncolytic Virus and Gene Therapy Fields Announce Formation of IGNITE Immunotherapy Inc., a Company Focused on Oncolytic Cancer Vaccine Discovery and Development
12 Dec 2016 Defymed Enters Partnership with Semma Therapeutics
12 Dec 2016 Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing
10 Dec 2016 AstraZeneca and Lilly to develop second potentially disease-modifying treatment for Alzheimer’s disease
09 Dec 2016 Complimentary copy of report „Blockbuster Biologics 2015: Sales of Recombinant Therapeutic Antibodies & Proteins“
09 Dec 2016 Forge Therapeutics and Evotec Form Strategic 'Superbug' Alliance

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing